Do weight loss injections work on the NHS — and are they right for you?

Picture where most people are when they ask this question

You've heard about Mounjaro or Wegovy (possibly from a friend, possibly from a headline) and you're wondering whether the NHS will give them to you and whether they actually deliver on the results being reported. Both are fair questions. The short answer on results is yes, the evidence is real and the trial data is from proper randomised controlled trials published in the New England Journal of Medicine, not social-media anecdotes. The short answer on NHS access is more complicated, and that's where most of the frustration lives.

These medicines work by mimicking the hormones your gut releases after eating. Semaglutide activates one receptor (GLP-1) that slows stomach emptying and reduces appetite. Tirzepatide activates two (GLP-1 and GIP), making it the only dual-agonist weight-loss medicine currently licensed in the UK. Neither is a stimulant or a crash diet in a pen. They change the biology of hunger, which is why weight loss injections have attracted serious clinical interest rather than just lifestyle-sector hype.

The trials that back them up involved thousands of adults. SURMOUNT-1, the key tirzepatide study, randomised 2,539 participants and saw up to around 22.5% average weight loss at the highest dose in some analyses. STEP 1, semaglutide's landmark trial, ran for 68 weeks and produced roughly 15% average reduction. These figures are averages, individual results vary, and no medicine guarantees a specific outcome for any one person.

What the NHS will actually provide right now

NICE has recommended both medicines, but the NHS is rolling out access in stages. If you want a clear picture of how weight loss injections work through the NHS, including eligibility criteria and what the rollout timetable looks like in practice, that detail is worth reading before you take any next steps. As things stand, tirzepatide on the NHS is available from June 2025 for adults with a BMI of 40 or above plus four or more of a defined list of conditions, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. A second cohort (BMI 35–39.9 with four or more of those conditions) became eligible from around June 2026. Further cohorts follow in 2027. Lower BMI thresholds apply for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, reflecting UK guidance on ethnicity-adjusted risk.

For semaglutide (Wegovy), the route on the NHS runs through specialist weight management services under NICE guidance TA875, which restricts it to a maximum of two years and requires multidisciplinary support. Waiting lists for those services are typically long. General practices can now prescribe tirzepatide under the 2026/27 GP contract, though participation is optional, so whether your surgery offers this depends on where you live.

It's worth being clear: meeting the criteria on paper doesn't guarantee access. Every NHS patient must take part in wraparound diet and activity support as a condition of treatment. If you're unsure whether you qualify or how to navigate a referral, understanding the NHS referral process is a practical first step.

Side effects: what you'll likely notice and what to watch for

Both medicines have a gastrointestinal side-effect profile, nausea, constipation, loose stools, reflux, and general digestive unsettlement are the most commonly reported effects, particularly in the weeks after starting or after a dose increase. For most people these settle. They're not trivial, but they're also not a reason to stop without talking to your prescriber first.

There are rarer but more serious effects to know about. In January 2026 the MHRA issued a Drug Safety Update flagging acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines. Severe stomach pain that spreads toward the back, especially with vomiting, should prompt same-day medical attention rather than waiting to see if it passes. Suspected side effects can be reported directly at yellowcard.mhra.gov.uk.

These medicines aren't recommended during pregnancy, while breastfeeding, or when trying to conceive. They're also not licensed for under-18s. Women taking oral contraceptives starting tirzepatide should use an additional non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide can reduce pill absorption, something worth knowing before you begin. A prescriber will go through all of this with you at consultation.

If the NHS route isn't open to you yet

A lot of people asking how weight loss injections work on the NHS have already quietly worked out that they probably don't meet the current thresholds. That's a genuinely frustrating position, you may be at a BMI where these medicines are licensed and clinically appropriate, but not at the specific NHS eligibility point the phased rollout has reached. If you're trying to understand how a weight loss injection is accessed through the NHS, including what a GP can and cannot do under the current contract, that guidance explains the practical reality more fully.

Private prescription is the legal alternative. It still requires a proper clinical assessment by a qualified prescriber, the medicine is a POM regardless of how it's obtained, and any source offering it without that assessment is operating outside the law. Cost context for private treatment is worth reading before you start comparing providers; prices vary considerably by dose and provider, and what's included in the headline figure varies even more. You can check any online pharmacy against the official GPhC register at pharmacyregulation.org before handing over personal or payment details.

If you're ready to find out whether you're suitable, payday timing and Monday orders both matter practically: at nume, orders placed before 12pm on a weekday are dispatched the same day once a prescriber has reviewed your case, with free next-working-day delivery via DPD. Our clinical team reviews every consultation personally. For a broader look at the treatment landscape, including the new weight loss injections coming through the NHS and how they fit alongside private options, our weight-loss overview covers what's available and how the different options compare.